Durvalumab

Status:
Do Not Prescribe (DNP), Red
Decision Date:
June 2019
 

Comments

RED:

  • NICE TA578: Locally advanced, unresectable non-small cell lung cancer after platinum-based chemoradiation.  (Decision date - June 2019).
  • NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. (NHSE commissioned).  (Decision date - July 2022).

 

DO NOT PRESCRIBE (DNP):

  • NICE TA662: in combination for untreated extensive-stage small cell lung cancer.  (Terminated appraisal).  (Decision date - December 2020).

Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app